Latest Breast Cancer News

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Imagion Biosystems has submitted its Investigational New Drug application to the U.S. FDA for its MagSense® HER2 Imaging Agent, marking a pivotal step toward launching a Phase 2 clinical trial for breast cancer detection.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Atlantic Lithium has submitted a revised Mining Lease for its flagship Ewoyaa Lithium Project to Ghana's Parliament, aligning fiscal terms with current legislation and awaiting final ratification. Meanwhile, promising exploration results in Côte d’Ivoire and a successful capital raise underpin the company’s growth ambitions.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

BCAL Diagnostics has launched its Avantect pancreatic and ovarian cancer tests in Australia, alongside expanding clinical data and establishing a national registry for its BREASTESTplus breast cancer test.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

BCAL Diagnostics has secured national ethics approval to establish a large-scale registry tracking the clinical impact of its BREASTESTplus blood test for breast cancer diagnosis, aiming to enhance doctor adoption and reimbursement prospects.

Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.